What does AP Biosciences Inc do?

AP Biosciences Inc (6945.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6945.TWO's market cap?

AP Biosciences Inc (6945.TWO) has a market capitalization of approximately $9.84 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 6945.TWO pay a dividend?

No — AP Biosciences Inc (6945.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6945.TWO profitable?

AP Biosciences Inc (6945.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6945.TWO

AP Biosciences Inc

TWO·Biotechnology · Healthcare

NT$101.50NT$1.50+1.50%

Market capNT$9.84B·Market closed·Aug 26 5:20 AM UTC

Price Chart

NT$101.50+NT$1.50 (+1.50%)today

+28.64%CAGR +8.41%

Select date range

FromTo

Jul 14, 2023Jul 14, 2023 → Aug 26, 2026· 3.1 yrsAug 26, 2026

Key Metrics

6945.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$0.00

Net Income−NT$444.77M

Net Margin—

Operating Cash Flow−NT$352.09M

Capital ExpendituresNT$25.03M

Free Cash Flow−NT$377.12M

Return on Equity−35.0%

Return on Invested Capital−19.3%

Net CashNT$1.11B

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6945.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6945.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6945.TWO and 80,000+ other tickers.

About AP Biosciences Inc

AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and…

CEO: Jeng-Horng Her
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 37
Website: www.apbioinc.com

Peers

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6945.TWO

What does AP Biosciences Inc do?: AP Biosciences Inc (6945.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6945.TWO's market cap?: AP Biosciences Inc (6945.TWO) has a market capitalization of approximately $9.84 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 6945.TWO pay a dividend?: No — AP Biosciences Inc (6945.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6945.TWO profitable?: AP Biosciences Inc (6945.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.